{"entity":{"id":"nct05827081","kind":"trial","name":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","aka":[],"tldr":"A phase 3 trial of Ribociclib and Exemestane in advanced solid tumours, run by Novartis Pharmaceuticals, now recruiting.","summary":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer is a phase 3 interventional study registered as NCT05827081 by Novartis Pharmaceuticals, with 1400 participants planned, started 2024-02-28 and due to reach its primary completion in 2029-09-07. Interventions recorded: Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide and Exemestane.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05827081","url":"https://clinicaltrials.gov/study/NCT05827081"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ribociclib","exemestane"],"companies":["advanced-accelerator-applications"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05827081","phase":"3","setting":"A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)","sponsor":"Novartis Pharmaceuticals","enrolled":1400,"outcomes":[]},"route":"/trials/nct05827081/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"}]}}